Liver Cancer
(Hepatoma / Hepatocellular Carcinoma / HCC)
CPMC Cancer Services
Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page
Further protocol information can be found on the links below at ClinicalTrials.gov
Active Trials
Title: A Randomized Phase III, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Everolimus (RAD001) in Adult Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment
Description: Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma
Investigator: Ari Baron, MD
Eligibility: Subjects with advanced HCC whose disease progressed while on or after sorafenib treatment or who are intolerant to sorafenib
Status: Active and open to enrollment
Contact: Brenda Eng, 415-600-1775,
Email: EngB@cpmcri.org about Study EVOLVE
Title: A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH)
Description: A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Patients With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib (REACH)
Investigator: Ari Baron, MD
Eligibility: Subjects with hepatocellular cancer that have failed on first-line therapy with sorafenib
Status: Active and open to enrollment
Contact: Brenda Eng, 415-600-1775,
Email: EngB@cpmcri.org about Study Imclone CP12-0919
Title: A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
Description: Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
Investigator: Ari Baron, MD
Eligibility: Subjects with advanced hepatocellular carcinoma that have not received treatment
Status: Active and open to enrollment
Contact: Angie Stone, 415-600-1477,
Email: StoneAR@cpmcri.org about Study MUSC 101282
Title: Phase II Trial of Sorafenib in Combination With Capecitabine for the Treatment of Patients With Measurable Hepatocellular Carcinoma
Description: This study will evaluate Sorafenib (Nexavar®) and Capecitabine (Xeloda®) to see how effective this combination of study drugs will be in treating HCC
Investigator: Ari Baron, MD
Eligibility: Subjects with measurable hepatocellular carcinoma
Status: Active and open to enrollment
Contact: Brenda Eng, 415-600-1775,
Email: EngB@cpmcri.org about Study INST 0820
- updated August 2011
Back to top